The Pro12 -->Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes.
about
A comprehensive review of genetic association studiesThe association between the Pro12Ala variant in the PPARγ2 gene and type 2 diabetes mellitus and obesity in a Chinese populationPPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism.Impact of nine common type 2 diabetes risk polymorphisms in Asian Indian Sikhs: PPARG2 (Pro12Ala), IGF2BP2, TCF7L2 and FTO variants confer a significant riskPro12Ala polymorphism in the PPARG gene contributes to the development of diabetic nephropathy in Chinese type 2 diabetic patients.Association of genetic polymorphism of PPARγ-2, ACE, MTHFR, FABP-2 and FTO genes in risk prediction of type 2 diabetes mellitusImpact of common variants of PPARG, KCNJ11, TCF7L2, SLC30A8, HHEX, CDKN2A, IGF2BP2, and CDKAL1 on the risk of type 2 diabetes in 5,164 Indians.Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-gamma2 gene variant: results from the Troglitazone in Prevention ofPPARG: Gene Expression Regulation and Next-Generation Sequencing for Unsolved Issues.The common PPAR-gamma2 Pro12Ala variant is associated with greater insulin sensitivity.Alanine for proline substitution in the peroxisome proliferator-activated receptor gamma-2 (PPARG2) gene and the risk of incident myocardial infarction.Impact of the Pro12Ala polymorphism of the PPARγ2 gene on diabetes and obesity in a highly consanguineous populationAssociation of the variants in the PPARG gene and serum lipid levels: a meta-analysis of 74 studies.The PPAR-gamma Pro12Ala polymorphism and risk of cognitive impairment in a longitudinal study.Relationship between PPARγ Pro12Ala gene polymorphism and type 2 diabetic nephropathy risk in Asian population: results from a meta-analysis.Studies of gene variants related to inflammation, oxidative stress, dyslipidemia, and obesity: implications for a nutrigenetic approachPeroxisome proliferator-activated receptor γ polymorphism Pro12Ala Is associated with nephropathy in type 2 diabetes: evidence from meta-analysis of 18 studiesThe Pro12Ala polymorphism in the PPAR-γ2 gene is not associated to obesity and type 2 diabetes mellitus in a Cameroonian populationVariation in Association Between Thiazolidinediones and Heart Failure Across Ethnic Groups: Retrospective analysis of Large Healthcare Claims Databases in Six CountriesGenetic approaches to studying common diseases and complex traits.Meta-analysis of association between the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-γ2 gene and diabetic retinopathy in Caucasians and AsiansPPAR-gamma in the Cardiovascular SystemGenetic polymorphisms of peroxisome proliferator-activated receptors and the risk of cardiovascular morbidity and mortality in a community-based cohort in washington county, Maryland.Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone.Implication of genetic variants near TCF7L2, SLC30A8, HHEX, CDKAL1, CDKN2A/B, IGF2BP2, and FTO in type 2 diabetes and obesity in 6,719 AsiansPeroxisome proliferator-activated receptors: new players in the field of reproduction.Does Pro(12)Ala Polymorphism Enhance the Physiological Role of PPARγ2?Association between PRO12ALA polymorphism of the PPAR-γ2 gene and type 2 diabetes mellitus in Iranian patientsPPARγ2 polymorphism and human health.Confirmation of multiple risk Loci and genetic impacts by a genome-wide association study of type 2 diabetes in the Japanese population.Association of PPARγ2 gene variant Pro12Ala polymorphism with hypertension and obesity in the aboriginal Qatari population known for being consanguineous.Impact of the Pro12Ala polymorphism of the PPAR-Gamma 2 gene on metabolic and clinical characteristics in the Palestinian type 2 diabetic patients.Impact of the PPAR-gamma2 Pro12Ala polymorphism and ACE inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: evidence from BENEDICTProliferator-activated receptor gamma Pro12Ala interacts with the insulin receptor substrate 1 Gly972Arg and increase the risk of insulin resistance and diabetes in the mixed ancestry population from South Africa.PPARG in Human Adipogenesis: Differential Contribution of Canonical Transcripts and Dominant Negative Isoforms.Ethnic difference in patients with type 2 diabetes mellitus in inter-East Asian populations: a systematic review and meta-analysis focusing on gene polymorphism.The association between the PPARγ2 Pro12Ala polymorphism and nephropathy susceptibility in type 2 diabetes: a meta-analysis based on 9,176 subjects.The association between lipid metabolism gene polymorphisms and nephropathy in type 2 diabetes: a meta-analysis.Impact of PPARgamma overexpression and activation on pancreatic islet gene expression profile analyzed with oligonucleotide microarrays.Implications of critical PPARγ2, ADIPOQ and FTO gene polymorphisms in type 2 diabetes and obesity-mediated susceptibility to type 2 diabetes in an Indian population.
P2860
Q22337119-8C3E051E-7A97-4B03-A04A-FF4D2C580F3CQ31132059-47CB82F6-35A8-43C3-90C9-9062F7A0AE6AQ33283063-399BE523-2480-4079-87DA-A1D9298EEA6DQ33348834-4D4F2B98-B937-4FE9-BA90-C3ABBA0A6FE6Q33556747-999ACE2C-FF51-4CFD-9355-20D0B2FEBD57Q33586532-213F52AC-ED0D-49CD-B47E-CC1DB078F083Q34024262-D717A425-B5B7-40F0-B1B1-FBD12BD2F8C8Q34085390-CEE511A2-0A79-4A36-BF88-EAA6C55DD43DQ34143718-1F3357E2-816E-4E49-91BF-B7853DE0B782Q34348367-618F6ED4-0AFE-426F-8802-71D3C4D0D19AQ34509923-B05D870A-187B-49CC-8777-1FDBE2D43C83Q34878443-327FDF4B-13CE-4DE7-87D9-AD7F5FD7FA45Q34885498-25324F88-5290-4D63-B7A0-CF30BCAD58BCQ34997212-90993D40-BC57-42DE-B2DA-2EDAAD6E4077Q35058771-DB04F368-5E38-4B57-9B41-72936237B94DQ35104849-8B1CF32C-DB57-4F9B-8134-27E0D7818D46Q35976372-4E488F0C-7424-4541-980E-4EA181D6CB61Q36033708-034D5665-4D40-4D92-BB11-36C280C47599Q36034337-66815C73-521F-4EEF-8A3D-84794F32C5E2Q36092154-7297DC78-54AA-4394-A0B4-DA59392F90A6Q36239731-A9B8EFEB-5B90-45ED-BE30-6BA7DFBFC40FQ36426786-A27F11EA-21B9-4F4C-A633-7C5C28321F9CQ36445100-A609BAFE-B999-4B4E-A0FD-DDD27D04B458Q36496755-877D3067-59A8-4FE0-87BB-37010AFDEE45Q36807593-46F426A8-2DF4-4FA3-9B35-8F553BC9FE1EQ36903108-0CE6300C-E472-42C4-837E-5073FFA7626AQ37105099-502C42B4-7DA5-4BCC-B396-0097574D74EBQ37136093-9D5D03AD-5072-48FF-8A46-1CB0E6C6C686Q37159796-AE671E92-20EC-4177-8A89-2E7E8CE441C9Q37236347-52E3A4E1-7C60-4B05-BFF0-E4ADEA3F3D5CQ37264986-8661EF30-EE8A-4955-A43F-AC8F01E67899Q37397885-749BB465-AA05-4ED7-8442-A9E7DC539C7BQ37429216-6D8E4CC3-E0F7-4F14-AD5B-50456ACC3299Q37509156-15FB9CFB-70D7-4AA6-B320-062990AE7089Q37694556-DD6AADDE-C108-43F7-A2DB-208A9E31DA63Q37798060-6875B6CA-35FF-41C8-BF05-613D862C04C7Q38121659-2ACEE6E3-3413-4C81-A73D-64E7871D56DCQ38254887-25101317-578D-43B6-BA39-FD41F9AEAC89Q38341682-18F05F5B-590D-4903-89D7-E66F8B5C0FACQ38561032-0DEC861E-2863-478A-A88B-D794AD1A50D7
P2860
The Pro12 -->Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
The Pro12 -->Ala substitution ...... ividuals with type 2 diabetes.
@en
The Pro12 -->Ala substitution ...... ividuals with type 2 diabetes.
@nl
type
label
The Pro12 -->Ala substitution ...... ividuals with type 2 diabetes.
@en
The Pro12 -->Ala substitution ...... ividuals with type 2 diabetes.
@nl
prefLabel
The Pro12 -->Ala substitution ...... ividuals with type 2 diabetes.
@en
The Pro12 -->Ala substitution ...... ividuals with type 2 diabetes.
@nl
P2093
P1433
P1476
The Pro12 -->Ala substitution ...... ividuals with type 2 diabetes.
@en
P2093
Hanafusa T
Kadowaki T
P304
P356
10.2337/DIABETES.50.4.891
P407
P577
2001-04-01T00:00:00Z